Advances in the pharmacological treatment of gastro-oesophageal cancer.
Despite a sharp decline in the incidence of gastric cancer during the second half of the 20th century, this malignancy remains the second leading cause of cancer mortality in the world. The incidence and mortality rate of gastric cancer increase with age; at present, the median ages at diagnosis are 67 years for men and 72 years for women in the US. This article reviews and discusses current medical treatment options for both the general population and elderly gastric cancer patients. Management of localized gastric cancer has changed significantly over recent years. Adjuvant chemoradiation is not generally recommended outside the US. After decades of trials of adjuvant chemotherapy with inconclusive results, a significant survival benefit for perioperative combination chemotherapy - as compared with surgery alone - in patients with resectable or locally advanced gastro-oesophageal cancer was recently demonstrated in the UK MAGIC trial. A further large, randomized trial from Japan demonstrated a significant survival benefit for adjuvant chemotherapy with S-1 after D2 resection for gastric cancer. However, both trials are applicable only to the population in which the trials were conducted. Specific data on elderly patients are missing. For patients with metastatic disease, oral fluoropyrimidines, such as capecitabine, have been developed. In Asian patients, treatment with the oral fluoropyrimidine S-1 is safe and effective. Docetaxel, oxaliplatin and irinotecan have demonstrated activity against gastric cancer in appropriately designed, randomized, phase III trials and have increased the available treatment options significantly. In addition, according to preliminary data, trastuzumab in combination with chemotherapy has significantly improved activity when compared to chemotherapy alone in patients with human epidermal receptor (HER)-2-positive gastric and gastro-oesophageal cancers. Thus, therapeutic decisions in patients with advanced gastric cancer may be adapted to the molecular subtype and co-morbidities of the individual patient. Data from retrospective analyses suggest that oxaliplatin seems to be better tolerated than cisplatin in elderly patients.
Wagner
Anna Dorothea
AD
Multidisciplinary Oncology Center, University of Lausanne Hospitals, Lausanne, Switzerland.
Wedding
Ulrich
U
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D015577:Geriatric Assessment; D006801:Humans; D010166:Palliative Care; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
D000970:Antineoplastic Agents
Am J Clin Oncol. 1999 Dec;22(6):580-6
10597742
Br J Cancer. 2008 Apr 22;98(8):1301-4
18362933
N Engl J Med. 2007 Nov 1;357(18):1810-20
17978289
J Clin Oncol. 2000 Jul;18(14):2648-57
10894863
Hematol Oncol Clin North Am. 2000 Feb;14(1):17-23
10680069
Cancer. 2000 Feb 15;88(4):921-32
10679663
N Engl J Med. 2008 Jan 3;358(1):36-46
18172173
J Clin Oncol. 2004 Nov 1;22(21):4319-28
15514373
Eur J Cancer. 2006 May;42(7):827-34
16466913
J Clin Oncol. 2007 Jun 10;25(17):2490-1; author reply 2491-3
17557965
J Clin Epidemiol. 2003 Jan;56(1):1-9
12589864
N Engl J Med. 2001 Oct 11;345(15):1091-7
11596588
Drugs. 2001;61(15):2309-26
11772141
JAMA. 2001 Jun 6;285(21):2750-6
11386931
Ann Oncol. 2000 Jul;11(7):837-43
10997811
J Pathol. 2007 Jan;211(1):45-51
17117405
Am J Clin Oncol. 2008 Jun;31(3):259-63
18525305
J Chemother. 2007 Feb;19(1):85-9
17309856
Eur J Surg. 2002;168(11):597-608
12699095
Br J Cancer. 2008 Aug 19;99(4):584-90
18665164
Clin Cancer Res. 1999 Jul;5(7):1696-702
10430071
Ann Oncol. 2004 Dec;15(12):1773-81
15550582
Eur J Cancer. 1999 Jul;35(7):1059-64
10533448
J Clin Oncol. 2006 Oct 20;24(30):4922-7
17050876
Crit Rev Oncol Hematol. 2008 Apr;66(1):84-90
18243012
J Clin Oncol. 1998 Apr;16(4):1582-7
9552069
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
16084735
BMC Cancer. 2006 May 10;6:125
16686939
Drugs. 2008;68(3):299-317
18257608
Ann Oncol. 2002 Oct;13(10):1568-75
12377644
J Am Geriatr Soc. 1991 Aug;39(8):778-84
1906492
J Clin Oncol. 1997 Jan;15(1):110-5
8996131
J Clin Oncol. 2002 Jan 15;20(2):494-502
11786579
Br J Cancer. 2003 Oct 20;89(8):1428-32
14562012
J Clin Oncol. 2007 Aug 1;25(22):3188-90
17664464
J Clin Oncol. 2003 Apr 1;21(7):1383-9
12663731
Clin Pharmacokinet. 2001;40(2):85-104
11286326
Ann Oncol. 2005 Feb;16(2):273-8
15668283
Br J Surg. 2007 Dec;94(12):1468-76
17948223
Ann Oncol. 2007 Mar;18(3):510-7
17164226
J Clin Oncol. 2003 Jan 1;21(1):54-9
12506170
Crit Rev Oncol Hematol. 2005 May;54(2):129-36
15843095
J Gen Intern Med. 2004 Oct;19(10):1027-33
15482555
Eur J Cancer. 1998 Jul;34(8):1274-81
9849491
Cancer Control. 2007 Jan;14(1):44-56
17242670
Cancer. 2002 May 15;94(10):2766-92
12173348
Ann Oncol. 2008 May;19 Suppl 2:ii23-4
18456755
Cancer. 1995 Mar 15;75(6 Suppl):1418-25
7889468
Ann Surg. 1998 Oct;228(4):449-61
9790335
Crit Rev Oncol Hematol. 2007 May;62(2):164-71
17169569
Ann Surg. 2002 Jul;236(1):37-42
12131083
N Engl J Med. 2001 Sep 6;345(10):725-30
11547741
J Clin Oncol. 2008 Mar 20;26(9):1443-51
18349394
Br J Cancer. 2000 Aug;83(4):458-62
10945491
Ann Oncol. 2008 Aug;19(8):1450-1457
18558665
J Clin Oncol. 2006 Sep 1;24(25):4085-91
16943526
Br J Cancer. 2005 Jun 20;92(12):2122-8
15942629
N Engl J Med. 1984 Dec 27;311(26):1664-70
6390207
Clin Gastroenterol Hepatol. 2003 Nov;1(6):438-45
15017643
N Engl J Med. 2006 Jul 6;355(1):11-20
16822992
J Clin Oncol. 2008 Mar 20;26(9):1435-42
18349393
Eur J Surg Oncol. 2003 Jun;29(5):450-4
12798750
J Clin Oncol. 2006 Nov 20;24(33):5201-6
17114652
Ann Oncol. 2004 Sep;15(9):1330-8
15319237
J Clin Oncol. 2005 Jan 20;23(3):494-501
15659494
JAMA. 2006 Feb 15;295(7):801-8
16478903
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004064
15846694
J Clin Oncol. 2005 Oct 1;23(28):6957-65
16145066
ANZ J Surg. 2006 Jun;76(6):458-61
16768768
Lancet Oncol. 2008 Mar;9(3):215-21
18282805
Crit Rev Oncol Hematol. 2007 Oct;64(1):1-9
17613243
J Clin Oncol. 2006 Nov 1;24(31):4991-7
17075117
Ann Oncol. 2009 Sep;20(9):1529-1534
19474114
Cancer Chemother Pharmacol. 1999;44(6):453-60
10550565